BioAmber (NYSE: BIOA) reported Q3 EPS of ($0.27), $0.14 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $2.3 million.

For earnings history and earnings-related data on BioAmber (BIOA) click here.